uvadex 20 mikrogramm/ml lösung zur modifikation einer blutfraktion
hospira methotrexate injection
pfizer new zealand limited - methotrexate 25 mg/ml (as methotrexate sodium) - solution for injection - 7.5 mg/0.3ml - active: methotrexate 25 mg/ml (as methotrexate sodium) excipient: sodium chloride sodium hydroxide water for injection - methotrexate may be of value in the symptomatic control of server, recalcitrant, disabling psoriasis which is not adequately responsive to other forms of treatment. however, due to the high risk associated with its use, methotrexate should be used after the diagnosis has been definitely established, as by biopsy and/or after dermatologic consultation.
cafnea
phebra pty ltd - caffeine -
dbl methotrexate injection
hospira australia pty ltd - methotrexate -
methaccord injection
accord healthcare pty ltd - methotrexate -
paracetamol & caffeine galpharm 500 mg & 65 mg tablets
galpharm healthcare limited - caffeine; paracetamol - tablet - 500/65 milligram(s) - anilides; paracetamol, combinations excl. psycholeptics
femara tablet 2.5 mg
novartis (singapore) pte ltd - letrozole - tablet, film coated - 2.5 mg - letrozole 2.5 mg
paracetamol / caffeine 500mg/65mg tablets
bristol laboratories limited - paracetamol; anhydrous caffeine - tablet - 500/65 mg/mg - anilides; paracetamol, combinations excl. psycholeptics
methaccord injection methotrexate 1000mg/10ml injection vial
accord healthcare pty ltd - methotrexate -
cafnea oral solution caffeine citrate oral solution 25 mg/5 ml oral administration vial
phebra pty ltd - caffeine, quantity: 12.5 mg - oral liquid, solution - excipient ingredients: citric acid monohydrate; sodium citrate dihydrate; water for injections - cafnea oral solution is indicated for the short-term treatment of apnoea of prematurity in infants between 28 and 33 weeks gestational age.